Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
Eledon Pharmaceuticals (Nasdaq: ELDN) will participate in the Leerink Partners 2026 Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eledon Pharmaceuticals (Nasdaq: ELDN) will participate in the Leerink Partners 2026 Global Healthcare Conference.
Chief Executive Officer David-Alexandre C. Gros, M.D. and President & Chief Scientific Officer Steven Perrin, Ph.D. will appear in a fireside chat on March 11, 2026 at 1:40 p.m. ET. A live webcast requires advance registration and a replay will be posted under Events on the company website.
Details
News Market Reaction – ELDN
On Mar 5, the first trading day after this news, ELDN closed 4.38% above the previous close.
Data tracked by StockTitan Argus for the Mar 5 session.
Key Figures
- Conference date
- March 11, 2026
- Leerink Partners 2026 Global Healthcare Conference fireside chat
- Fireside chat time (ET)
- 1:40 p.m. ET
- Scheduled start time for Leerink conference session
- Fireside chat time (PT)
- 10:40 a.m. PT
- Pacific Time equivalent for Leerink session
Historical Context
-
Announced fireside chat at Guggenheim Emerging Outlook: Biotech Summit 2026.
-
Reported 24‑month Phase 1b extension data in de novo kidney transplant patients.
-
Summarized 2025 milestones, Phase 2 BESTOW data, and $57.5M financing with 2026 outlook.
-
Announced CEO fireside chat at 37th Annual Piper Sandler Healthcare Conference.
-
Shared preliminary islet transplant data showing insulin independence in six T1D patients.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the upcoming Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026, at 1:40 p.m. ET (10:40 a.m. PT).
To register in advance for the fireside chat webcast, sign up here.
A webcast replay will be accessible following the live session on the Company’s website under Events.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.